Thursday, March 1st, 2018, Baltimore, MD - Insilico Medicine, a Baltimore-based company specializing in the application of artificial intelligence for drug discovery, biomarker development and aging research will present its latest research in artificially-intelligent target identification at the BioData World West Conference, 13th of March 2018, with the pre-conference workshop at NASA. In addition to the invited talk, Dr. Alex Zhavoronkov, the adjunct professor at the Buck Institute for Research on Aging and the CEO of Insilico Medicine will take part in the AI - Ethical Debate to discuss the challenges, opportunities and threats and ethical dilemmas presented by the modern AI.
Dr. Zhavoronkov's session "Developing new drug targets for aging through novel in silico methodologies" will cover the applications of novel tools for aging research and development of new aging biomarkers and drug targets.
The advances in modern AI present many ethical challenges and call for the formation of ethics boards and an open dialog among the captains of the industry. Insilico will take part in a keynote panel titled "AI - Ethical Debate" together with the experts from Google, Kaiser Permanente, Viz.ai and the World Economic Forum.
"The BioDataWorld West is one of the premium conferences in AI for Healthcare and this year. It brings together many of the industry leaders, government officials and foundations. 2018 is expected to be the year when the pharmaceutical industry realizes the potential of modern AI for drug and biomarker discovery and for clinical development and there will be many new startups, innovative partnering models and deals made this year. I hope that some of these will transpire at the BDWW18 ", said Alex Zhavoronkov, PhD, the founder and CEO of Insilico Medicine, Inc.
The BioData World West 2018 is the prominent innovative forum for healthcare executives focusing on Big Data, Precision Medicine, and Artificial Intelligence. In 2018 the pre-conference workshop will be organized at the NASA Ames center. The conference will bring together the world's thought leaders in AI. The program includes speakers from Roche, American Heart Association, GSK, NCI, NASA, Google, Merck, CLSA, UCSF, D-Wave and many other leading institutions.
"Insilico Medicine is one of the first companies to apply deep learning to drug discovery and biomarker development and presented their pioneering work at the many of our conferences. However, the group is well-known for exposing the ethical dilemmas presented by AI and we are happy to have them take part in our inaugural AI - Ethical Debate session", said Edward Glanville, the founder of the BioData World conference series.
Video presenting the BDDW17 conference.
Insilico Medicine is the first company to apply deep generative adversarial networks (GANs) to the generation of new molecular structures with specified parameters and published seminal papers in Oncotarget and Molecular Pharmaceutics. Another paper published in Molecular Pharmaceutics in 2016 and demonstrated the proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. One of the recent papers published in November 2017 described the application of the next-generation AI and blockchain technologies to return the control over personal data back to the individual. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The most recent paper published in the Oncotarget journal presented the roadmap to enhancing radioresistance for space exploration and colonization.
For further information, images or interviews, please contact:
Official Conference Website: http://www.
About Insilico Medicine, Inc
Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions.
The company utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI and Aging.AI and operates Chemistry.AI intended to capture the tacit knowledge of medicinal chemists.
Through a partnership with the BitFury Group, the company is working on a range of AI solutions for blockchain to help return the power over life data back to the individual. The company raised venture capital and partnered with Juvenescence Limited, a holding company focused on longevity biotechnology. The company aspires to become the "Bell Labs" for artificial intelligence and associated technologies for healthcare and longevity biotechnology and commercialize its research by forming subsidiaries around the specific technologies and licensing the intellectual property, molecules and data to the biotechnology and pharmaceutical companies. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. Brief company video: https:/